Shubert J. B. Melchers S. Sader, R. K. Flamm, J. M. Streit, R. N. Jones; JMI Lab., Inc., N Liberty, IA. Zhanel

49 SUNDAY SCIENTIFIC SESSIONS Final Program E-194 Avibactam NXL104 in Combination with Select ơ-Lactams and Meropenem Greatly Improves In Vitro Activity against ESBL-, AmpC-, and KPC-Producing Escherichia coli EC and Klebsiella pneumoniae KPN from Canadian Hospitals

A. Denisuik

1 , F. Tailor 1 , P. Lagacé-Wiens 1,2 , H. J. Adam 1,2 , D. J. Hoban 1,2 , G. G. Zhanel 1 , The Canadian Antimicrobial Resistance Alliance CARA; 1 Univ. of Manitoba, Winnipeg, Canada, 2 Diagnostic Services of Manitoba, Winnipeg, Canada. E-195 In Vitro Activity of Piperacillin-Tazobactam PT in Combi- nation combi with Various Antibiotics ABX against Extreme Drug-Resistant XDR Enterobacteriaceae EB with Reduced Susceptibilities to Polymyxin B PB T. P. Lim 1,2 , S. Sasikala 1 , W. Lee 1 , N. Tahir 1 , Y. Cai 1 , T. H. Koh 1 , T. Y. Tan 3 , L. Y. Hsu 2 , T. T. Tan 1 , A. L. Kwa 1 ; 1 Singapore Gen. Hosp., Singapore, Singapore, 2 Natl. Univ. Hosp. System, Singapore, Singapore, 3 Changi Gen. Hosp., Singapore, Singapore. E-196 In Vitro Susceptibility Among Enterobacteriaceae to a Novel ơ-Lactamơ-Lactam Inhibitor Combination: Cefpime-Tazobactam A. Manoharan, M. Sugumar, G. S. Barla, D. Kumar, D. Mathai; Christian Med. Coll., Vellore, Tamil Nadu, India. E-197 Utilizing Population Analysis to Investigate Piperacillin Tazobactam Differences Between Broth Microdilution and Agar Dilution for a Set of Escherichia coli

C. Shubert

1 , J. Slaughter 1 , D. Creely 1 , G. Zambardi 2 , D. Shortridge 1 ; 1 bioMerieux, Inc., Hazelwood, MO, 2 bioMerieux, Inc., La Balme, France. E-198 In Vitro Activity of Ceftolozane Alone and in Combination with Tazobactam against Extended Spectrum Beta-Lactamase Harbouring Enterobacteriaceae

M. J. B. Melchers

1 , C. H. van Mil 2 , J. W. Mouton 1 ; 1 Radboud Univ. Nijmegen Med. Ctr., Nijmegen, Netherlands, 2 Canisius Wilhelmina Hosp., Nijmegen, Netherlands. E-199 Activity of the Novel Antimicrobial CeftolozaneTazobactam Tested against Contemporary Clinical Strains from USA Hospi- tals 2011

H. S. Sader, R. K. Flamm, J. M. Streit, R. N. Jones; JMI Lab., Inc., N Liberty, IA.

E-200 In Vitro Activity of CeftolozaneTazobactam Tested against 1,705 Gram-Negative Pathogens Isolated from Patients in Canadian Hospitals in 2011: CANWARD Surveillance Study G. G. Zhanel 1 , H. Adam 2,1 , A. Walkty 2 , P. R. S. Lagace-Wiens 2 , D. J. Hoban 2,1 , J. A. Karlowsky 2 ; 1 Univ. of Manitoba, Winnipeg, Canada, 2 Diagnostic Services of Manitoba, Winnipeg, Canada. E-201 In Vitro Pharmacodynamics PD of Ceftolozane TOL Tazobactam TAZ against ơ-Lactamase BL Producing Eschericia coli Ec

R. L. Soon, A. Forrest, P. N. Holden, P. Kelchlin, B. T. Tsuji; Univ. at Buffalo, Buffalo, NY.